Modified mRNA vaccines encoding herpes simplex virus glycoproteins and uses thereof
AssigneeThe Trustees of the University of Pennsylvania
InventorsHarvey Friedman, Drew Weissman, Sita Awasthi, Gary Cohen
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions for the prevention and treatment of genital herpes, comprising nucleoside modified mRNAs that encode herpes simplex virus (HSV) glycoproteins, including those involved in virus entry and immune evasion, and methods of use thereof.
Claims17
A composition comprising a plurality of RNAs encoding HSV antigens, wherein the plurality of RNAs consist of:
- (a) RNA encoding an immunogenic fragment of a Herpes Simplex Virus (HSV) glycoprotein D (gD), wherein the immunogenic fragment consists of a sequence that is at least 95% identical to SEQ ID NO:
- 5;
- (b) RNA encoding an immunogenic fragment of an HSV glycoprotein C (gC), wherein the immunogenic fragment consists of a sequence that is at least 95% identical to SEQ ID NO:
- 11;
- and
- (c) RNA encoding an immunogenic fragment of an HSV glycoprotein E (gE), wherein the immunogenic fragment consists of a sequence that is at least 95% identical to SEQ ID NO:
- 17;
- wherein one or more of said RNAs is a nucleoside modified RNA.
A method of treating a Herpes Simplex Virus (HSV) infection or suppressing, inhibiting, or reducing the incidence of an HSV infection in a subject, the method comprising the step of administering a composition to said subject, wherein the composition comprises a plurality of RNAs encoding HSV antigens, wherein the plurality of RNAs consist of:
- (a) RNA encoding an immunogenic fragment of a Herpes Simplex Virus (HSV) glycoprotein D (gD), wherein the immunogenic fragment consists of a sequence that is at least 95% identical to SEQ ID NO:
- 5;
- (b) RNA encoding an immunogenic fragment of an HSV glycoprotein C (gC), wherein the immunogenic fragment consists of a sequence that is at least 95% identical to SEQ ID NO:
- 11;
- and
- (c) RNA encoding an immunogenic fragment of an HSV glycoprotein E (gE), wherein the immunogenic fragment consists of a sequence that is at least 95% identical to SEQ ID NO:
- 17;
- wherein one or more of said RNAs is a nucleoside modified RNA.
A method of inducing an immune response in a subject, comprising the step of administering a composition to said subject, wherein the composition comprises a plurality of RNAs encoding HSV antigens, wherein the plurality of RNAs consist of:
- (a) RNA encoding an immunogenic fragment of a Herpes Simplex Virus (HSV) glycoprotein D (gD);
- (b) RNA encoding an immunogenic fragment of an HSV glycoprotein C (gC);
- and
- (c) RNA encoding an immunogenic fragment of an HSV glycoprotein E (gE);
- wherein one or more of said RNAs is a nucleoside modified RNA.
Dependencies are inferred from the claim text.